LXEO Stock Analysis: Buy, Sell, or Hold?
LXEO - Lexeo Therapeutics, Inc. Common Stock
$4.20
0.07 (1.69%)
▲
5d:
-6.04%
30d:
-10.45%
90d:
-27.21%
HOLD
LOW Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When LXEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LXEO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LXEO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LXEO is currently trading at $4.20, which is considered oversold relative to its 30-day fair value range of $4.39 to $4.88.
Technical Outlook: Technically, LXEO is in a strong downtrend. Immediate support is located at $3.99, while resistance sits at $5.01.
Market Sentiment: LXEO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.89 (+397.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LXEO is in a strong downtrend. Immediate support is located at $3.99, while resistance sits at $5.01.
Market Sentiment: LXEO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.89 (+397.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.39 -
$4.88
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 397.4% below Wall St target ($20.89)
- CAUTION: Recommendation downgraded due to -6.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$4.39 -
$4.88
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.81
(19.2%)
Support & Resistance Levels
Support Level
$3.99
Resistance Level
$5.01
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.15
Wall Street Target
$20.89
(+397.4%)
Share & Embed Analysis
Last updated: August 04, 2026 9:11 AM ET
Data refreshes hourly during market hours. Next update: 10:11 AM
Data refreshes hourly during market hours. Next update: 10:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Nolan Townsend
SELL
55000 shares
2026-04-06
Jose Manuel Otero
SELL
3016 shares
2026-02-18
Richard Nolan Townsend
SELL
10173 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
